Savara (SVRA) Expected to Announce Earnings on Thursday

Savara (NASDAQ:SVRA) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Savara to post earnings of ($0.11) per share for the quarter.

Savara Trading Down 3.5 %

NASDAQ SVRA opened at $2.47 on Thursday. The company has a market capitalization of $423.90 million, a PE ratio of -5.74 and a beta of 0.63. The company has a fifty day moving average of $2.89 and a 200 day moving average of $3.51. Savara has a 1 year low of $2.44 and a 1 year high of $5.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 target price for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Thursday, December 19th. HC Wainwright cut their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Finally, Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Savara currently has an average rating of “Moderate Buy” and an average price target of $9.86.

Insider Activity at Savara

In related news, CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.13% of the stock is owned by corporate insiders.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.